Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer

European Urology

Volumn 61, Issue 2, 2012, Pages 363-369

  Pond, Gregory R ^a   Armstrong, Andrew J ^b   Wood, Brian A ^c   Brookes, Melissa ^c   Leopold, Lance ^c   Berry, William R ^d   De Wit, Ronald ^e   Eisenberger, Mario A ^f   Tannock, Ian F ^g   Sonpavde, Guru ^h,i  

^a MCMASTER UNIVERSITY   (Canada)

^b DUKE CANCER INSTITUTE   (United States)

^c Ascenta Therapeutics   (United States)

^d Raleigh Hematology Oncology Associates   (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g PRINCESS MARGARET HOSPITAL   (Canada)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

Docetaxel; Metastatic castration resistant prostate cancer; Prednisone

Indexed keywords

DOCETAXEL; ISOSORBIDE; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DRUG EFFICACY; EXPLORATORY RESEARCH; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; GOSSYPOL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 83955161760     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.06.034     Document Type: Article

References (17)

1. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
2. D.R. Berthold, G.R. Pond, F. Soban, R. de Wit, M. Eisenberger, and I.F. Tannock Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2008 242 245
3. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
4. H.I. Scher, S. Halabi, and I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
5. G. Sonpavde, V. Matveev, and J. Burke Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer J Clin Oncol 29 Suppl 7 2011 abstract 125
6. World Health Organization. WHO criteria. In: WHO handbook for reporting results of cancer treatment. (Offset publication no. 48.) Geneva, Switzerland: World Health Organization; 1979.
7. A.J. Armstrong, I.F. Tannock, R. de Wit, D.J. George, M. Eisenberger, and S. Halabi The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival Eur J Cancer 46 2010 517 525
8. W.K. Kelly, S. Halabi, and M.A. Carducci A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401 J Clin Oncol 28 Suppl 2010 abstract LBA4511
9. A.J. Armstrong, E. Garrett-Mayer, and Y.C. Ou Yang Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer J Clin Oncol 25 2007 3965 3970
10. D.P. Petrylak, D.P. Ankerst, and C.S. Jiang Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16 J Natl Cancer Inst 98 2006 516 521
11. T.M. Beer, C.W. Ryan, and P.M. Venner Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators J Clin Oncol 25 2007 669 674
12. J.S. De Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
13. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
14. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
15. T. Ciuleanu, T. Brodowicz, and C. Zielinski Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 2009 1432 1440
16. F. Cappuzzo, T. Ciuleanu, and L. Stelmakh Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
17. P.M. Fidias, S.R. Dakhil, and A.P. Lyss Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer J Clin Oncol 27 2009 591 598